Lai Quintin J 4

Accession 0001562180-23-006338

CIK 0000105770other

View on SEC.gov Company Profile

Filed

Aug 14, 8:00 PM ET

Accepted

Aug 15, 2:50 PM ET

Size

31.1 KB

Accession

0001562180-23-006338

Insider Transaction Report

Form 4

Period: 2023-08-11

WEST PHARMACEUTICAL SERVICES INCWST

Lai Quintin J

VP Corp Development & Strategy

Transactions

Exercise/Conversion
Common Stock
2023-08-11$89.64/sh+8,772$786,322→ 27,078.93 total
Exercise/Conversion
Common Stock
2023-08-11$102.51/sh+7,140$731,921→ 34,218.93 total
Exercise/Conversion
Common Stock
2023-08-11$173.22/sh+3,348$579,941→ 37,566.93 total
Exercise/Conversion
Common Stock
2023-08-11$274.29/sh+1,388$380,715→ 38,954.93 total
Exercise/Conversion
Common Stock
2023-08-11$369.13/sh+453$167,216→ 39,407.93 total
Sale
Common Stock
2023-08-11$394.62/sh−10,725$4,232,326→ 28,682.93 total
Sale
Common Stock
2023-08-11$395.54/sh−8,635$3,415,510→ 20,047.93 total
Sale
Common Stock
2023-08-11$396.12/sh−1,741$689,650→ 18,306.93 total
Exercise/Conversion
Stock Options (Right to Buy)
2023-08-11−3,348→ 1,116 total
Exercise: $173.22From: 2021-02-18Exp: 2030-02-18→ Common Stock (3,348 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-11−8,772→ 0 total
Exercise: $89.64From: 2019-02-20Exp: 2028-02-20→ Common Stock (8,772 underlying)
Exercise/Conversion
Stock Options (Right to buy)
2023-08-11−7,140→ 0 total
Exercise: $102.51From: 2020-02-19Exp: 2029-02-19→ Common Stock (7,140 underlying)
Exercise/Conversion
Stock Options (Right to buy)
2023-08-11−1,388→ 1,388 total
Exercise: $274.29From: 2021-02-23Exp: 2031-02-23→ Common Stock (1,388 underlying)
Exercise/Conversion
Stock Options (Right to buy)
2023-08-11−453→ 1,359 total
Exercise: $369.13From: 2023-02-22Exp: 2032-02-22→ Common Stock (453 underlying)

Footnotes (7)

[F1]The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $393.97 to $394.96, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
[F2]The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $394.97 to $395.93, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
[F3]The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $395.97 to $396.45, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
[F4]This option is fully vested.
[F5]This award vests in four equal annual installments beginning on February 18, 2021.
[F6]This award vests in 4 equal annual installments beginning on 2/23/2022.
[F7]This award vests in four equal annual installments beginning on February 22, 2023.

Documents

2 files

Issuer

WEST PHARMACEUTICAL SERVICES INC

CIK 0000105770

→

Entity typeother

Related Parties

filerCIK 0001744326

Filing Metadata

Form type: 4
Filed: Aug 14, 8:00 PM ET
Accepted: Aug 15, 2:50 PM ET
Size: 31.1 KB

View on SEC.gov